Biotechnology
Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs, […]
Read More
The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could […]
Read More
US Fda approves Vertex/CRISPR gene remedy for an inherited blood ailment
The headquarters of US biopharmaceutical firm Vertex Prescribed drugs in Boston, Massachusets, on November 4, 2023. Joseph Prezioso | Afp | Getty Visuals The U.S. overall health regulator has accepted Vertex Prescription drugs and CRISPR Therapeutics’ gene therapy to address a exceptional blood ailment requiring standard blood transfusions, in sufferers 12 several years and older, […]
Read More
ɺ trove of rebound possibilities': Strategists change bullish on biotech and much more, choosing leading stocks
2023 was not a good year for the overall health-treatment sector, but some traders be expecting it to make a comeback this 12 months — highlighting biotech and medical tech as parts to view. “Rising from a lousy money raising atmosphere in ’22-23, exactly where early-stage biotech firms grappled to fund their Research and Advancement […]
Read More
4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs , […]
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. […]
Read More
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan […]
Read More
CVS to close ‘select’ pharmacies in Target stores in the coming months
CVS Health plans to close select pharmacies inside Target stores early this year, a company spokesperson said Thursday, as retail pharmacy chains in the U.S. struggle to boost profits. The closures will begin in February and finish by the end of April, the spokesperson said in a statement. She added that employees affected by the […]
Read More
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment. […]
Read More
Moderna Covid vaccine sales plunge by two-thirds in 2023, but meet company's $6 billion forecast
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s forecast for the year, even as sales plummeted from the […]
Read More